首页> Blood> Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms.

Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms.

导出 LinkOut

翻译打印收藏纠错

第一作者： Nicole S,Arellano

第一单位： Division of Hematology and Hematological Malignancies, The University of Utah, Salt Lake City, UT.;Department of Oncological Sciences, The University of Utah, Salt Lake City, UT.

作者： Nicole S,Arellano ^[1] ; William L,Heaton ^[2] ; Mirielle C,Nauman ^[3] ; Abigail E,Runnels ^[2] ; Jacky,Gomez-Villa ^[3] ; Daniele,Vanni ^[4] ; Melissa,Gaviria ^[3] ; Maihi,Fujita ^[2] ; Nathan M,Krah ^[5] ; Michele,Ciboddo ^[3] ; Saveg,Yadav ^[2] ; Callie T,Brown ^[2] ; Parker D,Bowden ^[2] ; Amy K,Chen ^[3] ; Christopher,Henning ^[3] ; Silvia,Catricalà ^[6] ; Ilaria Carola,Casetti ^[7] ; Oscar,Borsani ^[8] ; Elisa,Rumi ^[8] ; Daniela,Pietra ^[6] ; Isabelle,Plo ^[9] ; Caroline,Marty ^[9] ; Marco,Marchetti ^[10] ; Ami B,Patel ^[1] ; Caner,Saygin ^[11] ; Shannon E,Elf ^[1]

作者单位： Division of Hematology and Hematological Malignancies, The University of Utah, Salt Lake City, UT.;Department of Oncological Sciences, The University of Utah, Salt Lake City, UT. ^[1] Division of Hematology and Hematological Malignancies, The University of Utah, Salt Lake City, UT. ^[2] Ben May Department for Cancer Research, The University of Chicago, Chicago, IL. ^[3] Ben May Department for Cancer Research, The University of Chicago, Chicago, IL.;Department of Molecular Medicine, University of Pavia, Pavia, Italy. ^[4] Division of Hematology and Hematological Malignancies, The University of Utah, Salt Lake City, UT.;Department of Biochemistry, The University of Utah, Salt Lake City, UT. ^[5] Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy. ^[6] Department of Molecular Medicine, University of Pavia, Pavia, Italy. ^[7] Department of Molecular Medicine, University of Pavia, Pavia, Italy.;Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy. ^[8] INSERM UMR1287, Gustave Roussy, Paris-Saclay University, Villejuif, France. ^[9] Utah Center for Genetic Discovery, Eccles Institute of Human Genetics, The University of Utah, Salt Lake City, UT. ^[10] Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL. ^[11]